Tonix Pharmaceuticals, Inc.

ACTIVE

26 Main St Ste 101, Chatham, New York, United StatesSubsidiary$8.0M

Part of Tonix Pharmaceuticals

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

35.3%

Phase 2

32.4%

Phase 3

32.4%

Trial Status Distribution

Active, not recruiting

2.9%

Completed

70.6%

Recruiting

2.9%

Terminated

17.6%

Withdrawn

5.9%

Clinical Trials

Trials sponsored by this organization (34)

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

Phase 2

Recruiting

interventional

Jun 2026360 participants

A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants

Phase 1

Active, not recruiting

interventional

Dec 202550 participants

Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)

Phase 2

Terminated

interventional

Aug 20243 participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

Phase 1

Completed

interventional

Jul 202326 participants

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

Phase 2

Completed

interventional

Mar 2023132 participants

A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine

Phase 2

Completed

interventional

Dec 202288 participants

Safety and Efficacy Study of TNX-102 SL in Participants With PTSD

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

Phase 2

Completed

interventional

Aug 202263 participants

Page 1 of 5

Approvals

No approval data available

News

No news articles found

Back to Organizations